Risk of major depression increases by 60% in patients with atopic dermatitis
Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognised as a mood disorder that…
By
Dermatology
Latest in
Dermatology
Amgen’s Phase III trial of ABP 654 meets primary efficacy endpoint
The trial assessed the safety and efficacy of ABP 654 versus Stelara in adults with moderate to severe plaque psoriasis.
Alopecia areata steals the spotlight in time for possible treatment paradigm shift
With alopecia areata in the headlines, Clinical Trials Arena looks at a potential shake-up in its drug options and an…
By
Over 50% of all atopic dermatitis cases go undiagnosed in key pharmaceutical markets
GlobalData epidemiologists have found that only around 40% of atopic dermatitis cases will be diagnosed in the 7MM this year.
By
MoonLake to begin Phase II trial of nanobody for hidradenitis suppurativa
The trial will analyse the safety and efficacy of varying doses of sonelokimab versus placebo in more than 200 subjects.
Vitiligo: all eyes on further Phase III data for Incyte’s ruxolitinib at AAD
With the FDA calling for more data on the JAK inhibitor in vitiligo, Incyte’s presentation is one to look out…
By
Ribon initiates Phase I trial of atopic dermatitis treatment
The single ascending dose and multiple ascending dose trial will analyse the safety and pharmacokinetics of RBN-3143.
Pipeline Moves: Sorrento terminates Phase Ib CAR-T pancreatic cancer trial, shot at further study drops
Kinnov Therapeutics in alcohol addiction and Genmab in fallopian tube cancer are also reviewed by Clinical Trials Arena.
By